Meredith E. K. Calvert

Meredith E. K. Calvert

Auto-generated profile, based on publicly available information

Meredith E. K. Calvert

Denali Therapeutics Inc., South San Francisco, CA 94080 USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MKMihalis S. Kariolis
Mihalis S. Kariolis
RWRobert C. Wells
Robert C. Wells
JGJennifer Alice Getz
Jennifer Alice Getz
WKWanda Kwan
Wanda Kwan
CMCathal S. Mahon
Cathal S. Mahon
YZY. Joy Yu Zuchero
Y. Joy Yu Zuchero
Engineering human IgG1 Fc binding to a brain endothelial cell–enriched receptor allows enhanced brain exposure of biotherapeutics in multiple species.

11 June 2022 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
DXDan Xia
Dan Xia
SLSteve Lianoglou
Steve Lianoglou
TSThomas Sandmann
Thomas Sandmann
MCMeredith Calvert
Meredith Calvert
Jung SuhJung Suh
Jung Suh
PSPascal E. Sanchez
Pascal E. Sanchez
Background: Genetic mutations underlying familial Alzheimer’s disease (AD) were identified decades ago, but the field is still in search of transformative therapies for patients. While mouse models based on overexpression of mutated transgenes have yielded key insights in mechanisms of disease, those models are subject to artifacts, including random genetic integration of the transgene, ectopic expression and non-physiological protein levels. The genetic engineering of novel mouse models using knock-in approaches addresses some of those limitations. With mounting evidence of the role played by microglia in AD, high-dimensional approaches to phenotype microglia in those models are critical to refine our understanding of the immune response in the brain. Methods: We engineered a novel App knock-in mouse model (AppSAA) using homologous recombination to introduce three disease-causing coding mutations (Swedish, Arctic and Austrian) to the mouse App gene. Amyloid-β pathology, neurodegeneration, glial responses, brain metabolism and behavioral phenotypes were characterized in heterozygous and homozygous AppSAA mice at different ages in brain and/ or biofluids. Wild type littermate mice were used as experimental controls. We used in situ imaging technologies to define the whole-brain distribution of amyloid plaques and compare it to other AD mouse models and human brain pathology. To further explore the microglial response to AD relevant pathology, we isolated microglia with fibrillar Aβ content from the brain and performed transcriptomics and metabolomics analyses and in vivo brain imaging to measure energy metabolism and microglial response. Finally, we also characterized the mice in various behavioral assays. Results: Leveraging multi-omics approaches, we discovered profound alteration of diverse lipids and metabolites as well as an exacerbated disease-associated transcriptomic response in microglia with high intracellular Aβ content. The AppSAA knock-in mouse model recapitulates key pathological features of AD such as a progressive accumulation of parenchymal amyloid plaques and vascular amyloid deposits, altered astroglial and microglial responses and elevation of CSF markers of neurodegeneration. Those observations were associated with increased TSPO and FDG-PET brain signals and a hyperactivity phenotype as the animals aged. Discussion: Our findings demonstrate that fibrillar Aβ in microglia is associated with lipid dyshomeostasis consistent with lysosomal dysfunction and foam cell phenotypes as well as profound immuno-metabolic perturbations, opening new avenues to further investigate metabolic pathways at play in microglia responding to AD-relevant pathogenesis. The in-depth characterization of pathological hallmarks of AD in this novel and open-access mouse model should serve as a resource for the scientific community to investigate disease-relevant biology.

26 February 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
AAAnnie Arguello
Annie Arguello
CMCathal S. Mahon
Cathal S. Mahon
MCMeredith E.K. Calvert
Meredith E.K. Calvert
DCDarren Chan
Darren Chan
JDJason C. Dugas
Jason C. Dugas
MKMihalis S. Kariolis
Mihalis S. Kariolis
Delivery of biotherapeutics across the blood–brain barrier (BBB) is a challenge. Many approaches fuse biotherapeutics to platforms that bind the transferrin receptor (TfR), a brain endothelial cell target, to facilitate receptor-mediated transcytosis across the BBB. Here, we characterized the pharmacological behavior of two distinct TfR-targeted platforms fused to iduronate 2-sulfatase (IDS), a lysosomal enzyme deficient in mucopolysaccharidosis type II (MPS II), and compared the relative brain exposures and functional activities of both approaches in mouse models. IDS fused to a moderate-affinity, monovalent TfR-binding enzyme transport vehicle (ETV:IDS) resulted in widespread brain exposure, internalization by parenchymal cells, and significant substrate reduction in the CNS of an MPS II mouse model. In contrast, IDS fused to a standard high-affinity bivalent antibody (IgG:IDS) resulted in lower brain uptake, limited biodistribution beyond brain endothelial cells, and reduced brain substrate reduction. These results highlight important features likely to impact the clinical development of TfR-targeting platforms in MPS II and potentially other CNS diseases.

20 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
NKNathalie Khoury
Nathalie Khoury
MPMichelle E. Pizzo
Michelle E. Pizzo
CDClaire B. Discenza
Claire B. Discenza
DJDavid Joy
David Joy
DTDavid Tatarakis
David Tatarakis
YZY. Joy Yu Zuchero
Y. Joy Yu Zuchero
Blood brain barrier-crossing molecules targeting transferrin receptor (TfR) and CD98 heavy chain (CD98hc) are widely reported to promote enhanced brain delivery of therapeutics. Here, we provide a comprehensive and unbiased biodistribution characterization of TfR and CD98hc antibody transport vehicles (ATVTfR and ATVCD98hc) compared to control IgG. Mouse whole-body tissue clearing reveals distinct organ localization for each molecule. In the brain, ATVTfR and ATVCD98hc achieve enhanced exposure and parenchymal distribution even when brain exposures are matched between ATV and control IgG in bulk tissue. Using a combination of cell sorting and single-cell RNAseq, we reveal that control IgG is nearly absent from parenchymal cells and is distributed primarily to brain perivascular and leptomeningeal cells. In contrast, ATVTfR and ATVCD98hc exhibit broad and unique parenchymal cell-type distribution. Finally, we profile in detail brain region-specific biodistribution of ATVTfR in cynomolgus monkey brain and spinal cord. Taken together, this in-depth multiscale characterization will guide platform selection for therapeutic targets of interest.

7 August 2025 in Science
Verified
Journal Article
Closed access
MPMichelle E. Pizzo
Michelle E. Pizzo
EPEdward D. Plowey
Edward D. Plowey
NKNathalie Khoury
Nathalie Khoury
WKWanda Kwan
Wanda Kwan
JAJordan Abettan
Jordan Abettan
YZY. Joy Yu Zuchero
Y. Joy Yu Zuchero
Amyloid-related imaging abnormalities (ARIA), side effects of anti-amyloid drugs seen in magnetic resonance imaging of the brain, are a major safety concern in patients with Alzheimer’s disease. We developed an antibody transport vehicle (ATV) targeting transferrin receptor (TfR) for brain delivery of anti-amyloid-β protein (anti-Aβ) using asymmetrical Fc mutations (ATV cisLALA ) that mitigates TfR-related liabilities and retains effector function when bound to Aβ. Administration of ATV cisLALA :Aβ in mice exhibited broad brain distribution and enhanced parenchymal plaque target engagement. This biodistribution reduced ARIA-like lesions and vascular inflammation. Taken together, ATV cisLALA has the potential to improve the next generation of Aβ immunotherapy through enhanced biodistribution mediated by transport across the blood-brain barrier.

18 August 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
BFBrittany N. Flores
Brittany N. Flores
SYSeungyoon B. Yu
Seungyoon B. Yu
ICIsaac V. Cohen
Isaac V. Cohen
MFMelania H. Fanok
Melania H. Fanok
WLWei Luan
Wei Luan
JLJoseph W. Lewcock
Joseph W. Lewcock
Neuronal TDP-43 aggregates are a hallmark ALS pathology. The integrated stress response (ISR) occurs downstream of TDP-43 pathology and may promote neurodegeneration. Here we demonstrate that a CNS penetrant small molecule eIF2B activator inhibits the ISR in cellular models of ALS and the brain of an inducible mouse model of TDP-43 pathology, where it transiently slowed progression of locomotor deficits and neurodegeneration. ISR activation was observed in ALS patient spinal cord and CSF. The investigational drug DNL343 was advanced into Phase 1 and Phase 1b randomized, double-blind, placebo-controlled trials in healthy and ALS participants, respectively (NCT04268784/NCT05006352); the primary objective in both studies was to investigate the safety and tolerability DNL343. DNL343 demonstrated a half-life supporting once-daily dosing and showed extensive CSF distribution. DNL343 was generally well tolerated and reduced ISR biomarkers in peripheral blood mononuclear cells and CSF of ALS participants. Therefore, DNL343 is a useful investigational drug to explore the effects of ISR inhibition in ALS models and individuals with neurological diseases.